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A B S T R A C T   
Chondroitin sulfate proteoglycans (CSPGs), up-regulated in and around the lesion after traumatic spinal cord 
injury (SCI), are key extracellular matrix inhibitory molecules that limit axon growth and consequent recovery of 
function. CSPG-mediated inhibition occurs via interactions with axonal receptors, including leukocyte common 
antigen- related (LAR) phosphatase. We tested the effects of a novel LAR inhibitory peptide in rats after hemi-
section at cervical level 2, a SCI model in which bulbospinal inspiratory neural circuitry originating in the 
medullary rostral ventral respiratory group (rVRG) becomes disconnected from phrenic motor neuron (PhMN) 
targets in cervical spinal cord, resulting in persistent partial-to-complete diaphragm paralysis. LAR peptide was 
delivered by a soaked gelfoam, which was placed directly over the injury site immediately after C2 hemisection 
and replaced at 1 week post-injury. Axotomized rVRG axons originating in ipsilateral medulla or spared rVRG 
fibers originating in contralateral medulla were separately assessed by anterograde tracing via AAV2-mCherry 
injection into rVRG. At 8 weeks post-hemisection, LAR peptide significantly improved ipsilateral hemi-
diaphragm function, as assessed in vivo with electromyography recordings. LAR peptide promoted robust 
regeneration of ipsilateral-originating rVRG axons into and through the lesion site and into intact caudal spinal 
cord to reach PhMNs located at C3-C5 levels. Furthermore, regenerating rVRG axons re-established putative 
monosynaptic connections with their PhMNs targets. In addition, LAR peptide stimulated robust sprouting of 
both modulatory serotonergic axons and contralateral-originating rVRG fibers within the PhMN pool ipsilateral/ 
caudal to the hemisection. Our study demonstrates that targeting LAR-based axon growth inhibition promotes 
multiple forms of respiratory neural circuit plasticity and provides a new peptide-based therapeutic strategy to 
ameliorate the devastating respiratory consequences of SCI.   
Abbreviations: AAV2, Adeno-associated virus serotype 2; C2 (3, 4, 5, etc.), Cervical spinal cord level 2 (3, 4, 5, etc.); CMAP, Compound muscle action potential; 
CNS, Central nervous system; CSPG, Chondroitin sulfate proteoglycan; CTB, Cholera toxin subunit B; ECM, Extracellular matrix; EMG, Electromyography; GAG, 
Glycosaminoglycan; GFAP, Glial fibrillary acidic protein; LAR, Leukocyte common antigen-related; NMJ, Neuromuscular junction; PhMN, Phrenic motor neuron; 
RPTP, Receptor protein tyrosine phosphatase; rVRG, Rostral ventral respiratory group; SCI, Spinal cord injury; VGLUT2, Vesicular glutamate transporter 2; 5-HT, 5- 
hydroxytryptamine. 
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1. Introduction 
Following traumatic spinal cord injury (SCI), functional deficits vary 
depending on the anatomical location, type and severity of the insult, as 
well as on the specific neural circuits affected (Ahuja et al., 2017). 
Approximately half of all SCI cases are located within the cervical spinal 
cord, with many of these individuals suffering from debilitating and 
persistent respiratory deficits and relying on mechanical ventilation for 
the remainder of their lives (Lane et al., 2008a). Despite surgical inter-
vention (e.g. vertebral bone stabilization), supportive and rehabilitation 
interventions, individuals affected by SCI carry a life-long risk for 
complications arising from motor, sensory and autonomic deficits. The 
limited ability of the injured spinal cord to repair itself remains a major 
barrier to achieving meaningful recovery of function after SCI. In 
particular, the severed axonal projections of damaged neurons are not 
capable of mounting a robust regenerative response after SCI, resulting 
in permanent disconnection of the neural circuits responsible for 
mediating various behaviors. 
Understanding the mechanisms that can drive a successful axon 
regrowth process after central nervous system (CNS) injury is critical to 
develop methods to therapeutically promote recovery of function in SCI 
and other neurological diseases. Without any intervention, spontaneous 
axon growth is extremely limited after SCI due in part to neuronal- 
extrinsic factors present in the injured CNS, including reactive scarring 
(Burda and Sofroniew, 2014), acellular cystic cavity formation (Kamada 
et al., 2011), excessive and persistent neuroinflammation (Zhu et al., 
2015), expression of various axon-growth inhibitory molecules (Beller 
and Snow, 2014), absence of trophic support (Robinson and Lu, 2017), 
and the inadequate spatiotemporal production of axon guidance mole-
cules to appropriately sculpt newly formed circuits (Sperry, 1963). In 
addition to environmental factors, axon growth in the injured adult CNS 
is limited by a number of important neuronal-intrinsic mechanisms such 
as the PTEN-mTOR signaling axis (Park et al., 2010). 
The extracellular matrix (ECM) plays essential roles in a variety of 
biological processes within both the intact and diseased nervous system 
such as cell migration, proliferation and differentiation. The ECM is also 
is a major source of axon growth inhibitors (Barros et al., 2011; Franco 
and Muller, 2011). In the CNS, the ECM is comprised of a number of 
different molecules, including chondroitin sulfate proteoglycans 
(CSPGs), non-collagenous glycoproteins, fibrillar collagens and hyalur-
onan (Benarroch, 2015; Fawcett, 2015). CSPGs are normally expressed 
in the intact spinal cord where they contribute to fundamental cellular 
processes. CSPGs can be significantly upregulated after CNS injury, 
resulting in growth inhibition of both damaged and spared axon pop-
ulations (Lang et al., 2015; Tran et al., 2018). Following insults to the 
CNS, increased CSPG secretion occurs in a number of cell types such as 
astrocytes, fibroblasts, pericytes and inflammatory cells, in particular 
within reactive scar tissue (Sharma et al., 2012). This upregulated CSPG 
expression mediates axon growth inhibition by signaling through re-
ceptors located on the membrane of axons, thereby limiting CNS plas-
ticity and repair (Bartus et al., 2012; Kwok et al., 2011; Xu et al., 2015). 
CSPGs can also induce caspase 3-mediated cell death in mature oligo-
dendrocytes and in populations of neural precursors such as oligoden-
drocyte progenitor cells (Dyck et al., 2019). By selectively cleaving the 
glycosaminoglycan (GAG) side chains of CSPGs (which are responsible 
for mediating a major portion of the axonal effects of CSPGs) via 
introduction of the bacterial enzyme chondroitinase ABC (ChABC), 
pioneering work has demonstrated that modulating the axon growth 
inhibitory impact of CSPGs after SCI can promote growth of injured and 
spared axons and some degree of functional recovery (Alilain et al., 
2011; Bradbury et al., 2002; Garcia-Alias et al., 2009; James et al., 2015; 
Ramer et al., 2014). CSPGs may therefore be an important therapeutic 
target for promoting repair following SCI. 
Structurally, proteoglycans contain a protein core and GAG side 
chains (chondroitin sulfate in the case of CSPGs). While it was initially 
believed that CSPGs mediated their axon growth inhibitory effects by 
steric hindrance of adhesion molecules that are growth promoting, the 
transmembrane protein tyrosine phosphatase-sigma (PTPσ) (Fry et al., 
2010; Shen et al., 2009) and related phosphatase leukocyte common 
antigen-related (LAR) (Fisher et al., 2011; Wong et al., 1993; Yang et al., 
1999) have been identified as the axonal receptors for the inhibitory 
actions of CSPGs. In addition to PTPσ and LAR, CSPGs can exert axon 
growth inhibitory effects via signaling through Nogo receptors 1 and 3 
(Dickendesher et al., 2012). LAR and PTPσ belong to the type IIa/LAR 
subfamily of receptor protein tyrosine phosphatases (RPTP), which in-
cludes the three vertebrate members LAR, PTPδ and PTPσ (Tonks, 
2006). Structurally, LAR RPTP contains an Ig-like domain that binds 
CSPGs, an extracellular fifth fibronectin type III domain, and an intra-
cellular wedge-shaped helix-loop-helix (Xie et al., 2020). The large 
extracellular regions of LAR RPTP can interact with additional extra-
cellular ligands besides proteoglycans (e.g. liprin-α, netrin-G ligand-3, 
TrkB) (Han et al., 2016; Takahashi and Craig, 2013), thereby mediating 
proteoglycan-regulated processes such as axon guidance and excitatory 
presynaptic and postsynaptic assembly (Fisher et al., 2011; Shen et al., 
2009). CSPGs bind to LAR RPTPs on the axon membrane to regulate a 
number of intracellular transduction pathways. This signaling can 
include stimulation of the RhoA kinase pathway and inactivation Akt 
and Erk pathways (Fisher et al., 2011) to restrict neurite outgrowth 
(Fisher et al., 2011; Lang et al., 2015; Xu et al., 2015). Deletion of LAR in 
knockout mice significantly overcomes CSPG-mediated neurite growth 
inhibition in neuronal culture (Fisher et al., 2011). Similarly, systemic 
treatment with LAR-targeting inhibitory peptides that block LAR activ-
ity in mice with thoracic transection SCI induces significant growth of 
descending serotonergic axons and also promotes locomotor functional 
recovery (Fisher et al., 2011). Additionally, inhibition of LAR promotes 
oligodendrogenesis from endogenous progenitor cells, attenuates cas-
pase 3-mediated cell death of mature oligodendrocytes, and preserves 
myelin after SCI (Dyck et al., 2018). Based on this body of work, LAR 
RPTP is a promising target for interventions that block the effects of 
CSPGs and provides an opportunity to enhance axon growth after CNS 
injury. 
Respiratory dysfunction is an extremely debilitating outcome of SCI 
that results in part from disruption of bulbospinal circuitry that controls 
the diaphragm, a primary muscle of inspiration (Warren et al., 2014). 
Phrenic motor neurons (PhMNs) located at cervical spinal cord level 3 
(C3)-5 (C5) innervate the ipsilateral diaphragm (Lane et al., 2009). 
These PhMNs receive primarily monosynaptic excitatory drive from 
rostral ventral respiratory group (rVRG) neurons located in medulla 
(Zimmer et al., 2007). PhMNs are also connected with rVRG neurons 
through poly-synaptic circuits involving pre-phrenic interneurons of 
cervical spinal cord (Lane et al., 2008b; Zholudeva et al., 2017). Cervical 
SCI damages this descending bulbospinal axon input to the PhMNs. As 
little growth of damaged axons occurs after SCI, PhMNs remain dener-
vated from their rVRG input, resulting in persistent partial-to-complete 
diaphragm paralysis. 
In a rat model of C2 hemisection-type SCI (Urban et al., 2019a; Urban 
et al., 2019b; Urban et al., 2018), we explored mechanisms of rVRG- 
PhMN-diaphragm circuit plasticity that can drive recovery of dia-
phragm function in response to manipulating axon growth inhibition. 
Specifically, we administered a novel LAR-targeting sequence-selective 
inhibitory peptide (abbreviated as LAR peptide) to the injured cervical 
spinal cord and assessed effects on diaphragm function using in vivo 
electrophysiological assays. In addition, we examined neuroanatomical 
effects of LAR inhibition on respiratory neural circuitry using antero-
grade and retrograde tracing approaches to quantitatively assess 
regeneration of injured rVRG axons, sprouting of spared rVRG fibers, 
and monosynaptic connectivity of these rVRG axon populations with 
PhMN targets located caudal to the lesion site. Furthermore, we took 
advantage of the observed animal-to-animal variability in LAR peptide- 
induced functional effects and axon growth responses to perform cor-
relation analyses to explore mechanisms of rVRG-PhMN-diaphragm 
circuit plasticity responsible for driving recovery of diaphragm function. 
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2. Results 
2.1. C2 hemisection SCI model and experimental design 
Hemisection of the cervical level 2 (C2) spinal cord from the midline 
to lateral edge has been used extensively to study respiratory plasticity 
following SCI (Bezdudnaya et al., 2017; Mantilla et al., 2017; Streeter 
et al., 2020). C2 hemisection axotomizes descending bulbospinal path-
ways originating in the rVRG of the medulla, thereby interrupting their 
connections to the PhMNs located at cervical levels C3-C5. Thus, a 
hemiparalysis of the diaphragm occurs ipsilateral to the injury, while the 
rVRG-PhMN-diaphragm circuit remains intact on the contralateral side. 
The hemisected animal is able to maintain ventilation due to preserva-
tion of both contralateral hemidiaphragm function and other non- 
Fig. 1. LAR peptide promoted recovery of diaphragm function after C2 hemisection SCI. (A) Timeline of experimental design. At 8 weeks post injury, EMG recordings 
were assessed at 3 sub-regions of both the ipsilateral and contralateral hemidiaphragm (dorsal, medial and ventral sub-regions) from C2 hemisection rats receiving 
either DMSO-only (B) or LAR peptide (C). (B, C) Representative EMG recordings from ipsilateral hemidiaphragm. Top: raw EMG traces; bottom: integrated signals. 
Quantification of integrated EMG amplitude 8 weeks after C2 hemisection at ventral (D) medial (E) and dorsal (F) sub-regions. n = 8–10 animals per group. Data 
represent mean ± SEM, *P < 0.05 vs the respective control. 
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diaphragm respiratory muscle pathways. C2 hemisection SCI is a 
powerful experimental model to mechanistically study plasticity of 
respiratory neural circuitry using neuroanatomical labeling of various 
components of this critically important circuit. In addition, various in 
vivo assays can be employed to assess recovery of diaphragm function in 
response to experimental manipulations, including therapeutic 
strategies. 
As shown in the experimental timeline (Fig. 1A), a biocompatible 
gelfoam was soaked with either DMSO vehicle- only control or LAR 
peptide and was placed directly over the SCI site immediately after C2 
hemisection. The gelfoam was then replaced with fresh peptide (or 
DMSO only) at 1 week post-injury. Two weeks post-SCI, we performed 
stereotaxic intra-medullary injection of an AAV2-mCherry vector to 
transduce either: (1) ipsilateral rVRG neurons or (2) contralateral rVRG 
neurons. At 7 weeks post- injury, we performed in vivo compound 
muscle action potential (CMAP) recording separately on each hemi-
diaphragm to evaluate functional innervation of the diaphragm by 
PhMNs. At 4 days after CMAP recording, we intrapleurally injected 
Cholera Toxin B Subunit to selectively label PhMN cell bodies within the 
cervical spinal cord. At 8 weeks post-injury, we performed in vivo 
electromyography (EMG) recordings during normal eupnic breathing to 
assess hemidiaphragm function, and animals were then euthanized for 
tissue collection. 
2.2. LAR peptide promoted recovery of diaphragm function after C2 
hemisection SCI 
Deficits in inspiratory diaphragm function can result from disruption 
at a number of possible locations along the rVRG-PhMN-diaphragm 
neural circuit, including rVRG axon status, rVRG axon-PhMN synaptic 
connectivity, PhMN health, phrenic axon-diaphragm synaptic connec-
tivity, and diaphragm muscle. In this study, we aimed to determine 
whether peptide-based LAR inhibition can restore diaphragm function 
after SCI and, importantly, by which mechanism of circuit plasticity this 
recovery occurs using a comprehensive set of neuroanatomical and in 
vivo functional assays. 
We first examined diaphragm function by quantitively measuring 
inspiratory bursting during normal eupnic breathing using in vivo EMG 
recordings of the hemidiaphragm ipsilateral to the SCI. As rVRG-PhMN 
disconnection after C2 hemisection results in nearly-complete EMG 
silencing of the ipsilateral hemidiaphragm, recovery of EMG amplitudes 
could be driven by LAR peptide-induced rVRG axon regeneration and 
synaptic reconnection with PhMNs. The diaphragm is a dome-shaped 
muscle at the base of the lungs, and under intact conditions, it con-
tracts and moves downward allowing the lungs to expand during 
inspiration; the diaphragm muscle relaxes during expiration. Ventral, 
medial and dorsal subregions of each hemidiaphragm correspond to 
innervation from PhMN cell bodies located at C3, C4 or C5 spinal cord, 
respectively (Laskowski and Sanes, 1987); therefore, conducting EMG 
recordings separately at each of these diaphragm subregions potentially 
allows for correlating functional EMG effects with neuroanatomical 
plasticity at these different spinal cord regions of the PhMN pool. 
In the DMSO-only control group, we observed almost-silenced EMG 
signals at all three subregions of hemi- diaphragm ipsilateral to the 
hemisection (Fig. 1B), confirming that C2 hemisection disrupts rVRG- 
PhMN-diaphragm signaling. On the contrary, we observed a signifi-
cant recovery of diaphragm EMG amplitudes at both ventral and medial 
sub-regions of ipsilateral hemidiaphragm after treatment with LAR 
peptide (Fig. 1C). Quantification of ipsilateral hemidiaphragm EMG 
amplitudes from each subregion was the following (in μV.s): ventral, 0.7 
± 0.1 for DMSO versus 2.7 ± 0.4 for LAR peptide, P < 0.001 (Fig. 1D); 
medial, 0.6 ± 0.1 for DMSO versus 1.4 ± 0.3 for LAR, P = 0.03, (Fig. 1E); 
dorsal, 0.6 ± 0.1 for DMSO versus 1.0 ± 0.1 for LAR, P = 0.4 (Fig. 1F), n 
= 8–10 rats per group for each subregion. We also compared EMG 
amplitude at all three subregions of hemidiaphragm contralateral to the 
hemisection and found no differences between DMSO-only and LAR 
peptide treated groups. Quantification of contralateral hemidiaphragm 
EMG amplitudes from each subregion was the following (in μV.s): 
ventral, 8.0 ± 0.4 for DMSO versus 8.8 ± 0.4 for LAR peptide (Fig. 1D); 
medial, 8.3 ± 0.4 for DMSO versus 8.7 ± 0.4 for LAR (Fig. 1E); dorsal, 
9.4 ± 0.3 for DMSO versus 8.2 ± 0.4 for LAR (Fig. 1F), P > 0.05 for all 
contralateral three subregions, one-way ANOVA, n = 8–10 rats per 
group for each subregion. These data from the contralateral hemi-
diaphragm show both that contralateral hemidiaphragm function was 
not altered by LAR peptide and that we do not encounter significant 
animal-to-animal variability in measuring diaphragm EMG amplitude. 
Overall, EMG data demonstrate that treatment with LAR peptide 
promotes ipsilateral hemidiaphragm functional improvement in vivo 
compared to DMSO-only control. We next sought to mechanistically 
explore how LAR inhibition is mediating this recovery. 
2.3. LAR peptide did not affect functional innervation of the diaphragm 
by PhMNs 
Diaphragm functional deficits after C2 hemisection (as well as LAR 
peptide experimentally-induced recovery) as reflected by EMG ampli-
tude could be caused by dysfunction at a number of points along the 
rVRG-PhMN-diaphragm pathway: central drive from rVRG neurons to 
PhMNs, PhMN drive to diaphragm, or diaphragm muscle fiber activa-
tion. We first tested whether hemisection-alone or LAR peptide treat-
ment altered functional innervation of the diaphragm by PhMNs. To do 
so, we performed in vivo quantitative recordings of CMAP amplitude 
from the ipsilateral or contralateral hemidiaphragm in response to 
supramaximal stimulation of the ipsilateral or contralateral phrenic 
nerve, respectively. Using this approach, we activate all phrenic motor 
axons and can then measure the post-synaptic depolarization response 
across all muscle fibers in the hemidiaphragm muscle. Representative 
traces of ipsilateral or contralateral hemidiaphragm CMAP responses are 
shown in Fig. 2 (A, B for DMSO-only control group; C, D for LAR peptide 
group). Quantitative analysis showed no differences in peak CMAP 
amplitude (Fig. 2E), duration (data not shown) or latency (i.e. time from 
stimulus to the initial CMAP deflection from baseline; data not shown) 
between DMSO-only control and LAR peptide groups, including in both 
the ipsilateral and contralateral diaphragm. The average peak CMAP 
amplitude ipsilateral to the injury site was 7.2 ± 0.5 mV for DMSO-only 
and 7.2 ± 0.7 mV for LAR peptide (n = 4 per group, P = 0.87, one-way 
ANOVA), while average peak CMAP amplitude contralateral to the 
hemisection was 6.7 ± 0.6 mV for DMSO and 6.6 ± 0.2 mV for LAR 
peptide (n = 4 per group, P = 0.88, one-way ANOVA). These data 
demonstrate that C2 hemisection did not alter functional innervation of 
the diaphragm by PhMNs compared to the intact side and that in hem-
isection animals LAR peptide treatment also did not affect functional 
diaphragm innervation. 
2.4. LAR peptide did not affect morphological innervation of the 
diaphragm by PhMNs 
Previous work from our lab and others demonstrated that cervical 
contusion-type SCI models that produce damage to PhMN cell bodies 
within the C3-5 spinal cord result in significant morphological dener-
vation at the diaphragm neuromuscular junction (NMJ) (Nicaise et al., 
2013; Nicaise et al., 2012a; Nicaise et al., 2012b), the critical synapse 
between phrenic motor axons and diaphragm muscle fibers. At eight 
weeks after injury, we morphologically determined whether NMJ 
innervation was compromised after C2 hemisection SCI and whether 
LAR peptide treatment affected this important synapse. Specifically, 
using whole-mount immunohistochemistry of the muscle, we labeled 
post-synaptic nicotinic acetylcholine receptors with fluorescently- 
conjugated alpha-bungarotoxin (red), and we labeled pre-synaptic 
phrenic motor axons all the way to their terminals with an antibody 
against neurofilament (SMI-312, green) and a second antibody against 
synaptic vesicle protein 2 (SV2, also green). As shown in representative 
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confocal z-stacks, nearly all NMJs in the ipsilateral hemidiaphragm were 
intact in C2 hemisection animals receiving either DMSO-only (Fig. 3A-F) 
or LAR peptide (Fig. 3G-L). Intact NMJs are characterized by complete 
apposition of the pre- and post-synaptic labeling. To quantitatively 
assess this innervation, we identified three primary NMJ morphologies: 
intact innervation (99.2 ± 0.4% of all NMJs in DMSO-only, n = 3 versus 
99.5 ± 0.3%, n = 4 in LAR peptide; P > 0.05 by ANOVA); partial 
denervation (0.25 ± 0.25% in DMSO, n = 3; 0.20 ± 0.20% in LAR 
peptide, n = 4; P > 0.05 by ANOVA), in which there is only partial 
overlap of the motor axon with the post-synaptic receptors; complete 
denervation (0.0 ± 0.0% in DMSO, n = 3 versus 0.0 ± 0.0% in LAR 
peptide, n = 4; P > 0.05 by ANOVA). There were no differences in the 
percentages of intact, partially-denervated or completely-denervated 
NMJs between rats treated with DMSO-only and LAR peptide 
(Fig. 3M). In addition, LAR peptide had no effect on the portion of NMJs 
innervated by multiple phrenic motor axons (0.67 ± 0.34% in DMSO, n 
= 3; 0.25 ± 0.25% in LAR peptide, n = 4; P > 0.05 by ANOVA) or the 
percentage of NMJs with thin preterminal axons, a phenotype indicative 
of denervation and subsequent reinnervation (0.0 ± 0.0% in DMSO, n =
3; 0.0 ± 0.0% in LAR peptide, n = 4; P > 0.05 by ANOVA) (Fig. 3M). 
These NMJ and CMAP results (i.e. absence of both functional and 
morphological denervation of the diaphragm by PhMNs on the side of 
hemisection SCI) were not unexpected given that the SCI was conducted 
at C2, which is just rostral to the rostral-most-part of the phrenic nu-
cleus. Combined with the CMAP findings, these NMJ data also demon-
strate that LAR peptide delivery did not promote functional recovery by 
affecting PhMN innervation of the diaphragm. 
2.5. LAR peptide promoted rVRG axon regeneration through the lesion 
and into the intact caudal spinal cord 
After CNS injury, damaged axons are unable to regenerate in mam-
mals without therapeutic intervention, including rVRG axons (Charsar 
et al., 2019; Urban et al., 2019a; Urban et al., 2019b). Even with 
experimental manipulation of axon growth inhibitory mechanisms 
(especially using non-genetic approaches), it is extremely challenging to 
achieve long-distance axon regeneration, in particular through the 
lesion site and back into the distal intact spinal cord where regenerating 
axons could connect with post-synaptic neuronal targets. To determine 
whether LAR peptide treatment promoted rVRG axon regeneration, we 
selectively labeled only rVRG axons by transducing rVRG neurons 
within the medulla ipsilateral to the hemisection with AAV2-mCherry 
(Fig. 4A). To determine whether our AAV2-mCherry labeling strategy 
was consistent across animals both within and across groups, we 
quantified the number of transduced rVRG cell bodies in the medulla. 
There was no difference in the number of AAV2-mCherry transduced 
rVRG neuron cell bodies between the two experimental groups (DMSO: 
19 ± 2 rVRG neurons per section; LAR: 24 ± 5, P = 0.32, t-test, n = 4 rats 
per group, Fig. 4C-E). 
To histologically verify lesion completeness before performing rVRG 
axon regeneration analysis, we performed both GFAP immunostaining 
(Fig. 4F-H) and and cresyl violet staining (data not shown) on cervical 
spinal cord sections from DMSO-only and LAR peptide rats. We found 
that the C2 hemisection was anatomically complete in every rat. In a 
separate cohort of rats receiving C2 hemisection-only (but no LAR 
peptide or DMSO-only treatment), we observed silencing of ipsilateral 
hemidiaphragm EMG activity at two weeks post-injury (i.e. a time point 
before the small amount of spontaneous ipsilateral EMG recovery occurs 
in the C2 hemisection model) in all tested animals (n = 5 rats; data not 
shown), further supporting the completeness of our lesion. While these 
EMG recordings at 2 weeks post-injury were not conducted in the 
injured rats receiving LAR peptide or DMSO-only, these data neverthe-
less support the consistent completeness of our C2 hemisection surgical 
procedure. 
In addition, we quantified lesion size to determine whether LAR 
peptide treatment impacted the histological extent of spinal cord dam-
age compared to the DMSO-only control group, which could contribute 
to LAR peptide-induced functional recovery. To measure lesion size, we 
performed GFAP immunohistochemistry on sagittal spinal cord sections 
to identify the border between intact tissue and lesion. We quantified 
rostral-caudal distance from the rostral to caudal borders of the lesion 
and found no difference between the experimental groups (Fig. 4F-H): 
393.8 ± 59.6 μm in DMSO-only group; 362.8 ± 36.6 μm in LAR peptide 
group, P = 0.67, t-test, n = 4 rats per group. These data suggest that a 
neuroprotective effect of LAR peptide was not involved in the observed 
functional diaphragm recovery. 
Transduction of the rVRG neuronal cell bodies resulted in antero-
grade labeling of rVRG axons within the cervical spinal cord. Sagittal 
spinal cord sections from animals with ipsilateral rVRG labeling were 
triple immunostained with DsRed (to enhance mCherry signal), vesic-
ular glutamate transporter 2 (VGLUT2) to label excitatory presynaptic 
terminals (as rVRG neurons are glutamatergic) and CTB (to selectively 
label PhMN cell bodies). CTB-labeled PhMNs were continuously 
distributed in a column within the ventral grey matter extending along 
levels C3 to C5 (Fig. 5A). rVRG axon regeneration was quantified as the 
number of mCherry tracer-labeled rVRG axons at different distances 
rostral to the lesion site, within the lesion, and in the caudal intact spinal 
cord (Fig. 5A). 
Both DMSO-only and LAR peptide treated animals showed rVRG 
axons rostral to the lesion (Fig. 5B,E). However, in the DMSO-only 
group, no rVRG axons were observed regrowing into or through the 
lesion (Fig. 5C) or into the caudal spinal cord (Fig. 5D), consistent with 
the results of our previous studies with untreated C2 hemisection-only 
conditions (Charsar et al., 2019; Urban et al., 2019a). In the LAR 
Fig. 2. LAR peptide did not affect functional innervation of the diaphragm by PhMNs. Representative CMAP recordings obtained from the ipsilateral and contra-
lateral hemidiaphragm of DMSO-only (A-B) and LAR peptide (C-D) groups. (E) Quantification of CMAP amplitudes showed no differences between the DMSO-only 
and LAR peptide groups or between ipsilateral and contralateral hemidiaphragm. n = 4 animals per group, P > 0.05. 
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peptide group, we observed significant growth of rVRG axons across the 
rostral intact-lesion interface, across the lesion site and across the caudal 
lesion-intact interface (Fig. 5F), and finally for several segments along 
the intact caudal spinal cord (Fig. 5G). Quantification of mCherry+ axon 
regrowth profiles at different rostral-caudal distances (Fig. 5H) shows 
that LAR peptide was effective at stimulating rVRG axon regeneration 
across an anatomically-complete SCI lesion, with these axons even 
reaching the C3 (corresponding to 1500 μm bar in Fig. 5H), C4 (corre-
sponding to 3000 μm bar in Fig. 5H) and C5 (corresponding to 4500 μm 
bar in Fig. 5H) spinal cord segments (asterisk indicates P < 0.05, 
ANOVA, n = 4 per group). Furthermore, to explore the relationship 
between rVRG axon regeneration and functional EMG improvement 
induced by LAR peptide, we examined the correlation between the de-
gree of rVRG axon regeneration at the C3 level and EMG amplitude in 
the corresponding ventral diaphragm subregion (Fig. 5I). There was a 
correlation between these two outcomes in the LAR peptide group 
(correlation coefficient for linear fit, R2 = 0.98, P = 0.01); data from 
DMSO-only control were not included in this analysis as absolutely no 
rVRG axon regeneration was observed in this group. These findings 
suggest that regeneration of rVRG axons across the lesion and into the 
intact caudal spinal cord (i.e. the location of the PhMN pool) was at least 
in part responsible for the recovery of diaphragm function induced by 
LAR peptide. 
2.6. LAR peptide promoted putative monosynaptic connection between 
regenerating rVRG axon and PhMNs 
Achieving long-distance axon regeneration following SCI is a major 
challenge. In addition to this axonal regrowth, it is also critical for these 
axons to synaptically connect with appropriate neuronal targets to 
promote recovery of function. This synaptic integration can include 
connectivity with the original post-synaptic targets of the axotomized 
neurons and/or generation of circuitry via novel connections. To 
investigate whether regenerating ipsilateral-originating rVRG axons 
formed synaptic connections with PhMNs on the side of hemisection SCI, 
we assessed the number of putative synaptic connections specifically 
between mCherry/DsRed-positive rVRG fibers and CTB-labeled PhMN 
cell bodies at level C3 using confocal acquisition of z-stacks and quan-
tification of rVRG axon-PhMN contacts using single-Z section analysis to 
establish direct apposition of pre-synaptic VGLUT2+/mCherry+ axon 
terminals and post-synaptic CTB+ PhMNs. We observed no putative 
rVRG-PhMN synapses in the DMSO-only control (Fig. 6A-D), as expected 
since no rVRG axon regeneration was achieved in this group. On the 
contrary, we observed large numbers of putative rVRG-PhMN synapses 
in the LAR peptide group (Fig. 6E-H). We quantified the number of these 
synaptic connections per individual PhMN at C3 and then plotted these 
data against the EMG amplitude results from the corresponding ventral 
subregion (Fig. 6I); there was strong correlation between these datasets 
(R2 = 0.99; P < 0.0001), further supporting the notion that rVRG axon 
regeneration and rVRG-PhMN circuit reconnectivity at least in part was 
responsible for LAR peptide-induced functional recovery. In addition to 
putative excitatory synapses between mCherry+ rVRG axons and 
PhMNs, we also quantified the effects of LAR peptide on excitatory 
synapses from mCherry− /VGLUT2+ non-rVRG inputs on ipsilateral 
CTB+ PhMNs at C3: 11.8 ± 0.9 putative mCherry− /VGLUT2+ excitatory 
synapses per CTB+ PhMN in DMSO-only group; 16.4 ± 1.9 in LAR 
treated group, P = 0.07, t-test, n = 4 rats per group, Fig. 6J. While not 
significant, the trend toward an increase suggests that LAR peptide may 
also enhance excitatory synaptic input to PhMNs from other neuronal 
populations in addition to rVRG axons (e.g. possibly from excitatory 
interneurons, sensory afferents, and various projection neuron pop-
ulations originating in supraspinal locations other than rVRG). 
2.7. LAR peptide promoted sprouting of rVRG axons within the PhMN 
pool 
Axon sprouting, defined as fine nerve processes or “sprouts” that 
grow out from injured or spared axons, has long been considered an 
important form of plasticity that can drive recovery of function both 
spontaneously and in response to therapeutic intervention following 
CNS damage (Meves and Zheng, 2014). We examined whether sprouting 
of spared rVRG axons originating in the contralateral medulla was 
induced by LAR peptide by injecting the AAV2-mCherry anterograde 
tracer into the contralateral rVRG and then quantifying sprouting of 
these axons within the PhMN pool on the side of the hemisection (i.e. 
contralateral to the location of their cell bodies) (Fig. 4B). Sagittal spinal 
cord sections were double-immunolabeled with DsRed and CTB. We 
then counted numbers of mCherry+ fibers within the phrenic nucleus (i. 
e. the location of CTB+ PhMNs) at distances of 1.5 mm, 3.0 mm and 4.5 
mm caudal to the lesion that correspond to C3, C4 and C5 levels, 
respectively (Fig. 7A). Representative confocal images show PhMNs 
labeled with CTB that were surrounded by contralateral-originating 
mCherry+ rVRG axons (Fig. 7B-G). We observed that these 
contralateral-originating rVRG axons are present within the PhMN pool 
on the side of hemisection even in the DMSO-only condition (Fig. 7D, H). 
The average number of these mCherry+ fibers in the LAR peptide group 
(11.8 ± 0.6, n = 5) increased significantly (P < 0.001, one-way ANOVA 
analysis, Fig. 7E-G, 7I, 7K) compared to DMSO-only control (3.4 ± 0.8, n 
= 5) at C3 (Fig. 7B-D, 7H, 7K) and C4 (2.7 ± 0.3 in DMSO, n = 5; 8.7 ±
1.3 in LAR peptide, n = 5; P = 0.002, one-way ANOVA, Fig. 7L), but 
there was no statistical significance in the difference at C5 (3.2 ± 0.8 in 
DMSO, n = 5 versus 7.1 ± 1.5 in LAR peptide, n = 5; P = 0.052, one-way 
ANOVA, Fig. 7M). We next examined whether there was a relationship 
between this sprouting and diaphragm functional recovery by assessing 
the correlation between the degree of rVRG axon sprouting at the C3 
level and EMG amplitude in the corresponding ventral diaphragm sub-
region (Fig. 7J). Unlike with the correlation between rVRG axon 
regeneration and EMG amplitude (Fig. 6I), we found no correlation 
between rVRG axon sprouting and diaphragm recovery (R2 = 0.75; P =
0.14). 
2.8. LAR peptide promoted sprouting of modulatory serotonergic axons 
within the PhMN pool 
Modulatory serotonergic axons whose cell bodies reside in one of 
several raphe nuclei of the brain play an important role in regulating the 
excitability of neuron populations across the CNS, in particular spinal 
cord lower motor neurons such as PhMNs (Fisher et al., 2011). 
Furthermore, plasticity of this serotonergic input has been shown to be 
involved in recovery of diaphragm function after cervical SCI, including 
both in the absence and presence of therapeutic intervention (Gosh-
garian, 2003; Perrin and Noristani, 2019). At 8 weeks post-injury, we 
assessed the density of serotonergic axon innervation within the PhMN 
pool by performing immunohistochemistry for serotonin (5-HT) and 
Fig. 3. LAR peptide did not affect morphological innervation of the diaphragm by PhMNs. Whole-mount immunohistochemistry of diaphragm was used to label post- 
synaptic nicotinic acetylcholine receptors with AlexaFluor- conjugated alpha-bungarotoxin (red) and pre-synaptic phrenic motor axons all the way to their terminals 
with an antibody against neurofilament (SMI-312, green) and a second antibody against synaptic vesicle protein 2 (SV2, also green). As shown in representative 
confocal z-stacks, nearly all NMJs in ipsilateral hemidiaphragm were intact in C2 hemisection animals receiving either DMSO-only (A-F) or LAR peptide (G-L). As 
shown in the higher magnification images, intact NMJs were characterized by complete apposition of the pre- and post-synaptic labeling. There were no differences 
in the percentages of intact, completely-denervated (Denv) or partially-denervated (P.Denv) NMJs, the portion of NMJs innervated by multiply phrenic motor axons 
(M.A.) or the percentage of NMJs with thin preterminal axons (T.S.) between rats treated with DMSO-only and LAR peptide (M). n = 3 for DMSO-only, n = 4 for LAR 
peptide. P > 0.05 vs the respective control. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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quantifying the total length of 5-HT+ axons. Compared to DMSO-only 
control (Fig. 8A-B), LAR peptide significantly increased the total 5-HT 
axon length within the phrenic nucleus at C3 (Fig. 8B-C) (3376 ± 779 
μm in DMSO versus 8473 ± 1562 μm in LAR peptide, n = 6 per group 
animals, P = 0.02, one-way ANOVA). However, LAR peptide did not 
affect the density of 5-HT axon innervation of the PhMN pool at C4 
(5135 ± 1861 in DMSO; 6952 ± 1501 in LAR peptide, n = 6 per group 
animals, P = 0.42, one-way ANOVA; Fig. 8D) or C5 (4973 ± 2109 in 
DMSO; 6657 ± 1461 in LAR peptide, n = 6 per group animals, P = 0.44, 
one-way ANOVA; Fig. 8E). 
Fig. 4. Labeling of rVRG-PhMN circuitry. (A) To determine whether LAR peptide treatment promoted rVRG axon regeneration, we selectively transduced rVRG 
neurons within the medulla ipsilateral to the hemisection with AAV2- mCherry. (B) In a separate cohort of rats, we examined whether sprouting of spared rVRG axons 
originating in the contralateral medulla was induced by LAR peptide by injecting the AAV2-mCherry anterograde tracer into the contralateral rVRG and then 
quantifying sprouting of these axons within the PhMN pool on the side of the hemisection (i.e. contralateral to the location of their cell bodies). In both cohorts, we 
intrapleurally injected Cholera Toxin B Subunit (CTB) to selectively label PhMN cell bodies within the cervical spinal cord. There was no difference in the number of 
AAV2-mCherry transduced rVRG neuron cell bodies in the medulla between the DMSO-only (C) and LAR peptide (D) groups (P = 0.32, n = 4 per group); quan-
tification in (E). Sagittal spinal cord sections immunolabeled for GFAP from DMSO-only control (F) and LAR peptide (G) show that LAR peptide did not alter lesion 
size after C2 hemisection. (H) Quantification of GFAP-labeled sections shows no difference in lesion size as measured by the rostral-caudal distance from the rostral to 
caudal borders of the lesion (P = 0.67, n = 4 rats per group). 
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3. Discussion 
3.1. Long-distance regeneration versus sprouting 
We find that LAR peptide administration resulted in both regenera-
tion of injured rVRG axons and sprouting of spared rVRG and seroto-
nergic axons. Our results are not in line with the body of work suggesting 
that modulating CSPG-mediated axon growth inhibition stimulates local 
sprouting and synaptic rearrangement but not long-distance regenera-
tion (reviewed in (Sofroniew, 2018)), though other studies have shown 
the axon regeneration promoting effects of targeting CSPGs after CNS 
injury (Bradbury et al., 2002). The current work and our previous 
studies (Urban et al., 2019b) demonstrate that rVRG axons are robust 
regenerators in response to targeting of growth inhibitory mechanisms; 
therefore, one possible explanation may be that the axon growth 
phenotype (i.e. regeneration versus sprouting) may differ with the spe-
cific axon population being examined. Interestingly, our previous work 
with a PTPσ inhibitory peptide showed functional diaphragm recovery 
in the C2 hemisection model (employing the same peptide delivery 
approach as we used for LAR peptide), but no regeneration of rVRG 
axons; instead, we found only sprouting of spared rVRG axons within the 
ipsilateral PhMN pool in response to PTPσ peptide (Urban et al., 2019a). 
These differences in the plasticity of rVRG-PhMN circuitry between LAR 
and PTPσ peptides may be explained by the findings that PTPσ and LAR 
can signal in part through non-overlapping intracellular transduction 
pathways that may be regulating different axon growth responses 
(Ohtake et al., 2016). Furthermore, our current and previous data 
collectively provide rationale for the combination of both PTPσ and LAR 
inhibition to maximize recovery via the simultaneous modulation of 
multiple signaling pathways and consequently multiple forms of axon 
growth (Ohtake et al., 2016). 
Using our analysis of only 40 μm thick spinal cord sections, we are 
not tracking regeneration of individual rVRG axons over long distances; 
therefore, caution is needed in making the conclusion that LAR peptide 
promoted regeneration of injured rVRG axons across the lesion site and 
back into the caudal intact C3-C5 spinal cord. However, we do clearly 
observe in every LAR-treated animal individual rVRG axons growing 
across the rostral intact-lesion interface into the lesion site, and we 
similarly observe in every LAR-treated animal individual rVRG axons 
growing across the caudal lesion-intact interface back into the caudal 
intact spinal cord. Furthermore, we never observe this in any animal in 
the DMSO-only control group. Therefore, while we have not followed 
individual axons along this entire journey, the data strongly suggest that 
they regenerated through the lesion. 
Findings in the field suggest that there is some double-crossed rVRG 
input to the PhMN pool originating in the ipsilateral rVRG (i.e. rVRG 
axons cross and then re-cross back as they descend from the medulla to 
the phrenic nucleus) (Boulenguez et al., 2007). Interestingly, we 
observed absolutely no ipsilateral-originating rVRG axon labeling 
within the PhMN pool ipsilateral to the hemisection in the DMSO-only 
control group, suggesting that the ipsilateral-originating rVRG axons 
that we observe at this location in the LAR peptide group made it there 
by growing through (and/or around) the lesion. This is supported by our 
observations of ipsilateral-originating rVRG axons growing into the 
lesion, across the lesion, and back out of the lesion into the distal/caudal 
spinal cord (even if we have not tracked single axons along this entire 
journey). Alternative explanations are possible, including that some of 
these ipsilateral-originating rVRG axons (that we observe in the ispi-
lateral PhMN pool in response to LAR peptide) are normally located in 
the contralateral cervical spinal cord and that LAR inhibition caused 
them to sprout across the spinal cord to reach the ipsilateral PhMN pool. 
This would not explain the lack of these ipsilateral-originating rVRG 
axons in the ipsilateral PhMN pool in the DMSO-only condition in the 
context of “double-crossing”, as we would expect to see them there even 
in the absence of therapeutic manipulation. It is possible that multiple 
plasticity mechanisms are occurring; nevertheless, our data strongly 
suggest that regeneration of injured ipsilateral-originating rVRG axons 
was significantly involved in the observation of these axons in the 
ipsilateral PhMN pool caudal to the hemisection. 
3.2. Mechanism of axon growth driving functional recovery 
In this study, we sought to determine which axon growth mechanism 
(s) stimulated functional diaphragm recovery in response to LAR pep-
tide. It is particularly challenging to determine the mode(s) of circuit 
plasticity causally responsible for recovery of function in an in vivo 
model of SCI. Along these lines, we have not definitively determined 
whether regeneration, sprouting or a combination of both drove dia-
phragm recovery, though we do provide a large amount of functional 
and neuroanatomical data that shed significant light on this important 
question. 
We observe significant regeneration of injured rVRG axons into and 
through the lesion site and, importantly, back into the distal intact spinal 
cord where they reach the cell bodies of the PhMNs ipsilateral to the 
hemisection. Interestingly, we find that this rVRG axon regeneration was 
the most robust at the C3 and C4 levels, with significantly less regen-
eration at the more caudal C5 segment (Fig. 5H). Correspondingly, we 
find diaphragm recovery with our EMG recordings only at the ventral 
and medial subregions of the muscle that are innervated by PhMNs 
primarily located at C3 and C4, respectively, but not at the dorsal sub-
region that is controlled by C5 PhMNs (Fig. 1 D-F). In addition, we find 
that there is some degree of animal-to-animal variability in both EMG 
recovery and rVRG axon regeneration in response to LAR peptide and 
that this recovery is strongly correlated with the amount of rVRG axon 
regeneration (Fig. 5I). Similarly, EMG recovery correlated with the de-
gree of rVRG-PhMN monosynaptic connections within the ipsilateral 
spinal cord (Fig. 6I). Collectively, these data suggest that rVRG axon 
regeneration was possibly responsible - at least in part - for driving 
functional diaphragm recovery. 
In our published work with a PTEN antagonist peptide, we also found 
robust rVRG axon regeneration and diaphragm recovery in the C2 
hemisection model (Urban et al., 2019b). In this previous study, we 
found that re-lesion through the hemisection site completely ablated 
recovery, demonstrating that regeneration through the injury site was 
causally responsible specifically for PTEN inhibition-induced improve-
ment and more generally that long-distance axon regeneration is a 
growth mechanism that can lead to diaphragmatic recovery after SCI 
(which has also been shown by Alilain and colleagues (Alilain et al., 
Fig. 5. LAR peptide promoted rVRG axon regeneration through the lesion and into the intact caudal spinal cord. (A) Sagittal section of cervical spinal cord showing 
the columnar organization of CTB-labeled PhMNs extending from C3 to C5, the locations (i.e. rostral-caudal distances relative to the hemisection site) of rVRG axon 
growth analysis, and the location of the representative images in panels B-G; scale bar in (A): 250 μm. Representative images of sagittal sections from DMSO-only or 
LAR peptide treated rats injected with AAV2-mCherry into the ipsilateral rVRG: (B,E) rostral to lesion site, (C,F) lesion site, (D,G) caudal to lesion site. These images 
from the two groups were always taken from the same rostral-caudal position/distance relative to the lesion epicenter. Yellow arrows in panels B-G denote mCherry- 
labeled rVRG axons. Dotted yellow lines in panels C and F denote the rostral and caudal lesion-intact borders. Scale bar: 100 μm. (H) Quantification shows the 
numbers of ipsilateral-originating mCherry-labeled rVRG axons at different locations in DMSO-only and LAR peptide group using the rostral end of the lesion as the 
rostral-caudal starting point. The indicated differences were compared between DMSO-only and LAR peptide groups at each distance (n = 4 animals per group, *P <
0.05). (I) Pearson Correlation was used to examine the correlation between the degree of rVRG axon regeneration at the C3 level and EMG amplitude in the cor-
responding ventral diaphragm subregion (correlation coefficient for linear fit, R2 = 0.98, P = 0.01, n = 4 animals per group). (For interpretation of the references to 
colour in this figure legend, the reader is referred to the web version of this article.) 
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Fig. 6. LAR peptide promoted putative monosynaptic connection between regenerating rVRG axon and PhMNs. We assessed the number of putative synaptic 
connections specifically between mCherry/DsRed-positive rVRG axons and CTB-labeled PhMN cell bodies at level C3 with confocal acquisition of z-stacks and 
quantification of rVRG axon-PhMN contacts using single-Z section analysis to establish direct apposition of pre-synaptic VGLUT2+/mCherry+ axon terminals and 
post-synaptic CTB+ PhMNs. Representative images in panels A-H are compressed z-stacks. (A-D) We observed no putative rVRG-PhMN synapses in the DMSO-only 
control. (E-H) On the contrary, we observed large numbers of putative rVRG-PhMN synapses in the LAR peptide group. (I) Orthogonal projection shows mCherry+/ 
VGLUT2+ excitatory rVRG axon terminals located directly presynaptic to the soma of a CTB+ PhMN (example putative connections denoted by arrowheads). Scale 
bar: 100 μm. Quantification of the number of these synaptic connections per individual PhMN at C3 plotted against the EMG amplitude from the corresponding 
ventral subregion in LAR peptide group (R2 = 0.99; P < 0.0001, n = 4). (J) Quantification of the effects of LAR peptide on putative excitatory synapses from 
mCherry− /VGLUT2+ non-rVRG inputs per ipsilateral PhMN at C3 (P = 0.07, n = 4 rats per group). 
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2011). We did not perform a similar re-lesion experiment in the current 
study with LAR peptide, leaving the possibility open that input from the 
spared contralateral spinal cord was the key mechanism (or that the 
combination of input from both the ipsilateral and contralateral sides 
together promoted functional improvement). To this point, we found 
significant sprouting within the ipsilateral PhMN pool of spared rVRG 
axons originating in the contralateral rVRG (Fig. 7). This finding is in 
line with a number of studies that have shown that CSPG modulation in 
the injured CNS promotes local sprouting (Sofroniew, 2018). Further-
more, sprouting of spared circuitry is an important plasticity mechanism 
that has been shown to promote functional recovery in SCI models both 
spontaneously and in response to therapeutic interventions (Bareyre 
et al., 2004). Importantly, achieving long-distance axon regeneration 
and reconnection of original circuitry is not necessary for promoting 
recovery after SCI. In the context of respiratory neural circuitry, spared 
contralateral-originating rVRG input plays a central role in the small 
amount of diaphragm recovery that occurs after C2 hemisection SCI, 
both spontaneously and in response to various manipulations (Gosh-
garian, 2003). Enhancing this spared input to the phrenic nucleus is a 
potentially powerful approach for stimulating respiratory recovery post- 
SCI. Interestingly, we observed rVRG axon sprouting at C3 and C4, but 
not at C5, which corresponds to the pattern of EMG recovery at two of 
the three diaphragm subregions. However, we did not find a correlation 
between the degree of rVRG axon sprouting and EMG amplitude 
(Fig. 7J), suggesting that this plasticity mechanism may not have played 
a role in recovery (or played a lesser role than rVRG axon regeneration). 
In another of our previous studies, we found in the C2 hemisection 
model that PTPσ inhibitory peptide promoted recovery of diaphragm 
function in the absence of any rVRG axon regeneration (Urban et al., 
2019a). Instead, PTPσ peptide stimulated robust sprouting of rVRG 
axons within the ipsilateral phrenic nucleus, and we observed that re- 
lesion through the hemsiection site had no effect on diaphragm recov-
ery, demonstrating that functional efficacy was based primarily on input 
from the spared contralateral spinal cord after PTPσ inhibition. 
Furthermore, we observed serotonergic axon sprouting within the 
ipsilateral phrenic nucleus at C3, but not at C4 or C5. These data may 
suggest that the combination of the highest level of rVRG axon regen-
eration in the C3 spinal cord plus 5-HT axon sprouting at this same 
location together produced the most significant EMG recovery in the 
ventral diaphragm subregion, which is in line with the modulatory effect 
of serotonergic input on glutamatergic neurotransmission in spinal 
motor neurons (Dale-Nagle et al., 2010). Functional recovery was also 
noted in the medial diaphragm; however, this recovery was not as robust 
as in the ventral diaphragm, and it was accompanied by lesser rVRG 
axon regeneration to the C4 spinal cord and an absence of 5-HT axon 
sprouting within the C4 portion of the ipsilateral PhMN pool. It is sur-
prising that we found increased density of 5-HT axons within the C3, but 
not C4 or C5 PhMN pool, if this effect was due to a sprouting response. 
Instead, we would expect to see equivalent 5-HT axon sprouting across 
the phrenic nucleus. A possible explanation is that the greater density of 
5-HT axons at C3 is due instead to regeneration of 5-HT axons across the 
lesion site, with these axons first reaching C3 and then not extending 
farther in the caudal direction. A number of studies have demonstrated 
growth of serotonergic axons in response to manipulation of CSPG 
signaling after SCI. For example, Lang and colleagues showed that de-
livery of a PTPσ inhibitory peptide stimulates significant 5-HT axon 
growth caudal to the thoracic SCI site, as well as recovery of bladder 
function (Lang et al., 2015). In the context of damaged respiratory cir-
cuitry, we have shown that PTEN antagonist peptide (Urban et al., 
2019b), PTPσ inhibitory peptide (Urban et al., 2019a), BDNF-releasing 
hydrogel (Ghosh et al., 2018) and intraspinal injection of an AAV2- 
BDNF vector (Charsar et al., 2019) each can promote 5-HT axon 
sprouting within the PhMN pool in C2 hemisection and mid-cervical 
contusion models of SCI. Warren and colleagues also showed that 
Chondroitinase ABC delivery can promote significant serotonergic axon 
growth and diaphragm recovery in the chronically injured cervical 
spinal cord (Warren et al., 2018). Collectively, our studies and the work 
of others in the field suggest that plasticity of serotonergic input to 
PhMNs is an important mechanism for stimulating diaphragmatic re-
covery after SCI and that targeting CSPG signaling via LAR and PTPσ 
manipulation is a promising approach for achieving this goal. 
An intriguing possibility is that different circuit plasticity mecha-
nisms were responsible for driving recovery at different portions of the 
PhMN pool in response to LAR inhibition. Going forward, it will be 
important to utilize experimental approaches such as selective silencing 
of specific neuronal populations using techniques like chemogenetics 
(Roth, 2016) to explore this issue more comprehensively and with 
greater experimental precision. 
Another possible explanation for our observation of functional re-
covery at the ventral and medial (but no dorsal) muscle subregions could 
be due to a LAR peptide gradient, with the highest peptide levels closest 
to the site of gelfoam delivery at C2 and progressively decreasing levels 
at more caudal locations along the PhMN pool contributing (completely 
or in part) to the differential functional effects observed across the three 
muscle sub-regions. Moving forward, we could begin to explore this idea 
by measuring peptide levels at different neuroanatomical locations. 
3.3. Synaptic connections 
The improvement of diaphragm function with LAR peptide could 
have been due to direct effects on synaptic rearrangement instead of (or 
in addition to) axon growth responses. Such synaptic effects could 
modulate the input from spared and/or regenerating axon populations. 
Previous work has shown that RPTPs such as LAR and PTPσ play an 
important role in synaptic development, in particular of excitatory 
synapses (Takahashi and Craig, 2013; Um and Ko, 2013). In this study, 
we find significant numbers of putative monosynaptic connections be-
tween regenerating rVRG axons and PhMN somata across the phrenic 
nucleus. As we observe absolutely none of these putative synapses in the 
DMSO-only control condition, the generation of these synapses may 
have been due just to LAR peptide promoting rVRG axon regeneration, 
with some of these regenerating axons making connections with PhMNs 
because of proximity and not because LAR inhibition directly enhanced 
synaptogenesis. We did not quantify monosynaptic connections between 
contralateral-originating rVRG axons and PhMNs in our study; going 
forward, this could be a useful approach to explore this question as we 
could control for the density of rVRG axons surrounding the PhMN 
somata and thereby assess LAR peptide’s effects specifically on levels of 
Fig. 7. LAR peptide promoted sprouting of rVRG axons within the PhMN pool. (A) Sagittal section of cervical spinal cord showing the columnar organization of CTB- 
labeled PhMNs extending from C3 to C5, the locations of rVRG axon growth analysis, and the location of the representative images in panels B-D as well as E-G. 
Sagittal spinal cord sections were double-immunolabeled with DsRed (to enhance the mCherry signal) and CTB. We counted numbers of mCherry+ fibers within the 
phrenic nucleus (i.e. the location of CTB+ PhMNs) at distances of 1.5 mm, 3.0 mm and 4.5 mm caudal to the lesion that correspond to C3, C4 and C5 levels, 
respectively; scale bar in (A): 250 μm. Representative confocal images show PhMNs labeled with CTB that were surrounded by mCherry+ rVRG axons. Contralateral- 
originating rVRG axons are present within the PhMN pool on the side of hemisection in both the DMSO-only (B-D) and LAR-peptide treated (E-G) conditions. (H, I) 
Yellow arrows indicate mCherry-labeled rVRG axons only. Scale bars: 100 μm. (F) The number of these mCherry+ fibers in the LAR peptide group increased 
significantly compared to DMSO-only control at C3 (E-I, K) and C4 (L), but there was no significant difference at C5 (M) (P < 0.05). (G) Pearson Correlation was used 
to examine the correlation between the degree of rVRG axon sprouting at the C3 level and EMG amplitude in the corresponding ventral diaphragm subregion in the 
LAR peptide group (correlation coefficient for linear fit, R2 = 0.75; P = 0.14, n = 5). (For interpretation of the references to colour in this figure legend, the reader is 
referred to the web version of this article.) 
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Fig. 8. LAR peptide promoted sprouting of modulatory serotonergic axons within the PhMN pool. At 8 weeks after hemisection SCI, we assessed the density of 
serotonergic axon innervation of the PhMN pool on the side of injury by performing immunohistochemistry for serotonin (5-HT) and quantifying the total length of 5- 
HT+ axons. Sagittal sections of the cervical spinal cord show that, compared to DMSO-only control (A), LAR peptide significantly increased 5-HT axon sprouting 
within the ipsilateral phrenic nucleus at C3 (B–C) at 8 weeks post-injury (n = 6 animals per group, *P = 0.02). However, LAR peptide did not affect the density of 5- 
HT axon innervation of the ipsilateral PhMN pool at C4 (D; P = 0.42) or C5 (E; P = 0.44). Scale bar: 100 μm. Arrowheads indicate 5-HT+ axons. 
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synapse formation independent of sprouting. 
3.4. Immune cell response 
Development and function of the immune system is regulated by 
RPTPs such as LAR and PTPσ (Pike and Tremblay, 2013). Furthermore, 
intraspinal inflammatory cell responses after SCI affect axon growth 
processes such as dieback and regrowth (Silver et al., 2014). Therefore, 
it is possible that LAR peptide indirectly impacted rVRG and seroto-
nergic axon growth via primary effects on inflammatory processes 
within the lesion and in the surrounding intact spinal cord. Interestingly, 
PTPσ genetic knockout or peptide-based inhibition worsen autoimmune 
responses in a mouse model of multiple sclerosis (Ohtake et al., 2017), 
suggesting that LAR inhibition could worsen outcome after cervical SCI 
by magnifying the proinflammatory response and therefore not produce 
the beneficial effects we observe in the current study. However, like 
other biological processes regulated by proteoglycan signaling, the ef-
fects of RPTP activation depend on the specific receptor (e.g. LAR versus 
PTPσ effects can differ). In addition, the immune cell effects of signaling 
can vary depending on whether the ligand is CSPG or another proteo-
glycan such as HSPG that can produce in some cases drastically different 
biological outcomes (Ohtake et al., 2018). Relative to PTPσ, little is 
known about the role of LAR in immune cell function (Kondo et al., 
2010; Terszowski et al., 2001), particularly in the context of nervous 
system pathophysiology. Future work will be needed to explore the 
contribution of immune cell modulation to LAR peptide effects after SCI. 
3.5. Source of CSPGs acting on LAR 
Findings in the field are beginning to suggest that a major portion of 
the axon growth- inhibitory CSPGs is not provided by reactive astrocytes 
around the lesion, but instead by non-astrocyte sources such as other 
scar-forming cell types (Anderson et al., 2016; Cregg et al., 2014). 
Importantly, an ongoing body of work (Smith et al., 1986; Smith et al., 
1987; Smith et al., 1990; Smith and Silver, 1988), including exciting 
recent studies (Anderson et al., 2016), suggests that astrocytes are axon 
growth-promoting, contrary to long-established beliefs. Astrocyte- 
mediated mechanisms that may be capable of promoting regeneration 
of damaged axons and sprouting of spared fibers include: (1) providing a 
cellular substrate for axon extension in the cystic lesion; (2) provision of 
beneficial molecules such as neurotrophins (Davies et al., 2006; Haas 
et al., 2012; Hamby and Sofroniew, 2010; Hill et al., 2004); (3) pro-
duction of extracellular matrix and cell adhesion molecules (Falnikar 
et al., 2015); and (4) immunomodulation (Sofroniew, 2015). Further-
more, therapeutic approaches aimed at enhancing the presence of pro- 
regenerative astrocytes using strategies such as transplantation of 
astrocyte progenitors or differentiated astrocytes have shown success in 
promoting axon growth in animal models of CNS trauma, including SCI 
(Davies et al., 2006; Davies et al., 2008; Haas and Fischer, 2013; Haas 
et al., 2012; Shih et al., 2014; Smith et al., 1986; Smith et al., 1987; 
Smith et al., 1990; Smith and Silver, 1988). 
3.6. Conclusions and future directions 
Excitingly, we have shown that inhibition of LAR via a peptide-based 
approach results in significant recovery of diaphragm function, rela-
tively long-distance regeneration of descending respiratory axon pop-
ulations and partial reconnection of damaged rVRG-PhMN-diaphragm 
circuitry in a severe model of high-cervical SCI. Moving forward, it will 
be important to extend this work to test delivery at a more delayed time 
point post-injury, including in a chronic SCI model given the large 
population of individuals that are chronically injured (Ahuja et al., 
2017). In this study, we employed a relatively-invasive peptide delivery 
approach involving surgical placement of the soaked gelfoam on the 
dorsal surface of the spinal cord. It will be critical to determine whether 
we can also achieve similar therapeutic efficacy with less-invasive 
methods such as systemic or intrathecal delivery (Urban et al., 
2019b). We have previously shown that systemic delivery of PTEN 
antagonist peptide can promote diaphragm recovery in this same hem-
isection model (Urban et al., 2019b), suggesting that a similar approach 
with our LAR peptide may be feasible. In this study, we restricted our 
approach to only a single peptide dosing and duration paradigm. It will 
be interesting to determine whether we can enhance therapeutic effects 
with a modified peptide delivery protocol. In addition to LAR peptide, 
there exist a number of possible approaches to modulate CSPG signaling 
such as enzymatic GAG side chain removal from CSPGs (Bradbury et al., 
2002), antibody-based (Wu et al., 2017) or small molecule (Keough 
et al., 2016) targeting of LAR and PTPσ, and modulation of other RPTPs 
besides LAR such as PTPσ (Urban et al., 2019a). It will be interesting 
moving forward to compare the therapeutic efficacy, potential side ef-
fects and various practical advantages and disadvantages of these 
different approaches in cervical SCI models and specifically on respira-
tory improvement. Finally, it is unlikely that LAR inhibition alone will 
be sufficient for achieving maximal functional recovery. Our current 
work demonstrates the therapeutic power of this novel LAR peptide 
approach and also provides extensive data suggesting the plasticity 
mechanisms by which LAR inhibition can affect respiratory neural cir-
cuitry. Going forward, it will be important to test the combination of 
LAR peptide with other strategies targeting axon growth inhibitory and 
promoting mechanisms, as well as interventions such as rehabilitative 
training regimens (Fuller and Mitchell, 2017), to promote additive – or 
even synergistic – therapeutic effects on respiratory function following 
SCI. 
3.7. Experimental procedures 
3.7.1. Animals 
Adult female Sprague-Dawley rats weighing 250–350 g from 
ENVIGO (formally Harlan Laboratories) were used in this study. Male 
animals were not used in this study. Rats were housed in a controlled 
environment (12 h light/dark cycles) with food and water ad libitum. All 
experimental procedures involving animals were performed under the 
approval of the Institutional Animal Care and Use Committee (IACUC) of 
the Thomas Jefferson University. Animal surgeries and pre- and post- 
surgical care were performed in compliance with ARRIVE (Animal 
Research: Reporting of In Vivo Experiments) Guidelines for the Care and 
Use of Laboratory Animals. Prior to surgery, animals were randomly 
assigned into the following groups: DMSO-only vehicle control or LAR 
peptide. All surgeries and subsequent functional and histological ana-
lyses were always performed in a blinded manner. DMSO-only treated 
animals served as vehicle controls and were subjected to the same 
procedures as the LAR peptide animals, with the only exception that the 
LAR peptide was not administered. 
3.7.2. Spinal cord injury (SCI) and postoperative care 
Anesthesia was induced with xylazine (10 mg/kg, s.q.) (Akorn Inc., 
Lake Forest, Illinois) and ketamine (120 mg/kg, i.p.) (Vedco, Saint Jo-
seph, Missouri). The skin overlying the dorsal side of spinal cord was 
shaved and disinfected (betadine and 70% ethanol wipes) before sur-
gery. A midline longitudinal incision was made from the base of the skull 
to the shoulder blades through the skin and muscle overlying the cer-
vical vertebrae. A laminectomy was performed to expose the C2 spinal 
cord and a right C2 hemisection was performed caudal to the C2 rootlets 
from the midline to lateral edge of the spinal cord using a micro-scalpel 
(Urban et al., 2018). To ensure a complete hemisection, a 30-gauge 
needle (BD Biosciences, San Jose, California) was passed through the 
lesion several times. Following complete hemisection, the overlying 
muscles were sutured with sterile 4–0 Vicryl suture, and the skin was 
closed with sterile wound clips (Braintree Scientific, Braintree, Massa-
chusetts). Rats were given antisedan (1.2 mg/kg, s.q.) (Zoetis, 
Parsippany-Troy Hills, New Jersey), lactated Ringer’s solution (10 ml, s. 
q.) and buprenorphine (0.01 mg/kg, s.q.) (Patterson Veterinary, 
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Greeley, Colorado) immediately after surgery. Rats were then placed in 
a clean cage on a surgical heating pad set to 37 ◦C (Gaymar, Orchard 
Park, New York) continuously for 5 days. Lactated Ringer’s solution (30 
ml/day, s.q.) and oral Nutri-cal supplements (1–3 ml/day, Vetoquinol 
USA Inc., Fort Worth, Texas) were provided until adequate normal 
eating and drinking resumed. Signs of pain/distress, respiratory distress 
and infections were closely monitored postoperatively. 
3.7.3. LAR peptide treatment 
LAR peptide was synthesized commercially with C-terminal amida-
tion by CHI Scientific, and peptide purity was analyzed by mass spec-
trometry. The peptide sequence was published previously (Fisher et al., 
2011). Lyophilized peptide was dissolved in DMSO and then diluted to 
the final concentration (15 mg/ml) in sterile calcium-free Hanks’ 
balanced salt solution. LAR peptide or DMSO-only vehicle were soaked 
in gel foam (3.0 mm length x 3.0 mm width x 2.5 mm depth in size) and 
placed directly over the lesioned spinal cord (50 μl/rat), both immedi-
ately after hemisection and again at 7 days post-injury. With respect to 
the experimental design of peptide delivery, we based this on both our 
preliminary experiments and practical considerations. However, it is 
important to point out that it is impossible to identify the perfect de-
livery paradigm. We choose to deliver the peptide with the soaked 
gelfoam approach, and we replaced the gelfoam with a fresh piece of 
soaked gelfoam only once at 7 days post-injury. We chose not to replace 
the gelfoam additional times for more prolonged delivery because each 
replacement involves an invasive spinal surgery. Therefore, our para-
digm was a balance of practicality and maximizing duration and dosing 
of delivery. We have shown that delivery of PTPσ peptide with this same 
gelfoam method promotes significant recovery of diaphragm function in 
C2 hemisection SCI rats (Urban et al., 2020). We waited until 8 weeks 
post-injury to perform functional analysis and to sacrifice the animals to 
provide sufficient time for axon growth and synaptic connectivity. A 
number of studies reported that SCI rodents maintain functional re-
covery after terminating peptide-based treatments that promote axon 
growth (Fisher et al., 2011; Lang et al., 2015; Li and Strittmatter, 2003). 
It is possible that we would observe similar functional and histological 
efficacy if animals were sacrificed at an earlier time point; however, we 
chose only the later time point for this study. 
3.7.4. Rostral ventral respiratory group (rVRG) injection 
We used adeno associated virus (AAV) serotype 2 driving expression 
of red fluorescent protein (AAV2-mCherry) to examine the distribution 
of bulbospinal rVRG projections to the phrenic motor nucleus (Urban 
et al., 2018). Rats were anesthetized with a mixture of ketamine/xyla-
zine. The head of each rat was fixed in a stereotaxic frame (David Kopf 
Instruments, Tujunga, CA) with the mouthpiece set at − 11 mm below 
the interaural line. The atlanto-occipital membrane was incised, and the 
lower aspect of the occipital plate was removed to allow penetration of 
the injection needle. Focal pressure injections of AAV2-mCherry (me-
dulla; titer: 1.66 × 10e13 vg/ml; volume: 0.3 μl controlled by Micro4 
Microsyringe Pump) were targeted to the medullary rVRG located at the 
following coordinates: 2.0 mm lateral, 1.0 mm rostral, and 2.6 mm 
ventral from calamus scriptorius, as determined in separate neuro-
physiological findings (Bezdudnaya et al., 2017; Zheng et al., 1998). In 
animals receiving C2 hemisection, brainstem and spinal cord tissues 
were harvested 4 weeks following AAV injection. 
3.7.5. Retrograde labeling of phrenic motor neurons (PhMNs) 
PhMNs were retrogradely and bilaterally labeled 3 days prior to 
tissue harvest (Li et al., 2014). Animals were induced with 3% isoflurane 
in 100% O2, and rats were transferred to a pad and anesthesia was 
maintained through a nose cone with 1.5–2% isoflurane. While stabi-
lizing the animal’s back, the rib cage was palpated in order to identify 
the fifth intercostal space at the anterior axillary line. Using sterile 
conditions and appropriate antisepsis, a 50-μl Hamilton syringe was 
used to inject 15–20 μl of a 0.25% Cholera Toxin B Subunit (CTB, 
Choleragenoid) from Vibrio cholera (List Biological Labs). Injections 
were performed transcutaneously into the intrapleural space on each 
side (5–7 mm deep, from skin). Animals were monitored closely for any 
signs of respiratory deficits such as that following unintentional pneu-
mothorax, but none were evident in all animals in this study. 
3.7.6. Electromyography (EMG) recordings and analysis 
All animals were anesthetized with xylazine (10 mg/kg, s.q.) and 
ketamine (120 mg/kg, i.p.). The skin overlying the abdomen was 
shaved, and an incision was made to expose the right and left hemi-
diaphragm. Bipolar electrodes spaced 3 mm apart were placed for 
recording in three separate sub-regions of the hemidiaphragm: dorsal, 
medial, and ventral. EMG activity (10,000 samples/s) was amplified and 
filtered through a band-pass filter (50–3000 Hz) by using a PowerLab 8/ 
30 data acquisition system (AD Instruments, Colorado Springs, Colo-
rado) (Li et al., 2015a). Recordings were made separately in each sub- 
region from each animal. Diaphragm EMG traces were rectified and 
integrated (time constant decay 0.05 s) using LabChart 7 software (AD 
Instruments, Colorado Springs, Colorado). For each muscle sub-region in 
an animal, diaphragm output was determined by averaging integrated 
signal across all inspiratory bursts from three 30-s intervals (30-s in-
tervals were selected that had no sighs) over the total five-minute 
recording time. 
3.7.7. Compound muscle action potential (CMAP) recordings 
Phrenic nerve stimulation and CMAP recordings were performed 
with ADI Powerlab 8/30stimulator and BioAMPamplifier (ADInstru-
ments) (Li et al., 2015b). Rats were anesthetized with isoflurane (Pira-
mal Healthcare, Bethlehem, Pennsylvania) at a concentration of 
2.5–3.0% diluted in oxygen. Rats lay supine and a ground electrode was 
placed subcutaneously into tail. Recording was obtained from the uni-
lateral costal margin via standard surface electrode. The reference 
electrode was placed subcutaneously into the contralateral lower 
abdominal region. The single stimulus duration was set to 0.5 millisec-
onds duration at 6 mV (amplitude). Stimulating electrodes were placed 
transcutaneously approximately 1.0 cm deep, 0.5 cm apart, lateral to the 
trachea and superior to the clavicle. After the single supramaximal 
stimulation, repetitive nerve stimulation (~ 10 times), with the 
recording and stimulating electrodes in the same positions, was applied 
to obtain the average response. A supramaximal CMAP was obtained, 
and the amplitude was measured from baseline to peak. 
3.7.8. Diaphragm whole-mount histological neuromuscular junction (NMJ) 
analysis 
For microscopic examination of whole-mount diaphragm, the dia-
phragm was dissected, rinsed in PBS (pH 7.4) and fixed in 4% para-
formaldehyde (PFA) in PBS at room temperature for 20 min. After the 
removal of connective tissue, the whole-mount diaphragm was incu-
bated in 0.1 M glycine for 30 min at room temperature. The post- 
synaptic nicotinic acetylcholine receptors in the diaphragm were 
labeled with α-Bungarotoxin, Alexa Fluor 555 conjugate (1:200, Invi-
trogen) at room temperature for 15 min. After washing, the whole- 
mount diaphragm was permeabilized with ice-cold methanol for 5 
min, and then were blocked for 1 h at room temperature in a Trition- 
BSA-PBS solution composed of 2% bovine serum albumin and 0.2% 
Triton X-100 diluted in PBS. The diaphragms were incubated with pre- 
synaptic vesicle marker anti-SV2 antibody (1:10, Developmental 
Studies Hybridoma Bank) and neurofilament marker anti-SMI-312 
antibody (1:1000, Covance) at 4 ◦C overnight. After washing with TBP 
solution, the diaphragms were incubated with Fluorescein (FITC) Affi-
niPure IgG, Fcγ subclass 1 specific secondary antibody (Jackson 
ImmunoResearch Laboratories) for 1 h at room temperature. Di-
aphragms were mounted with Vectashield mounting medium (Vector 
Laboratories), coverslipped and stored at − 20 ◦C. Two blinded re-
searchers quantified the whole-mount diaphragms under a Leica fluo-
rescence microscope. Total numbers of NMJs and percentages of intact, 
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partially-denervated or completely denervated NMJs were analyzed 
(Wright et al., 2009; Wright and Son, 2007). We morphologically eval-
uated NMJ innervation by quantifying five different NMJ phenotypes at 
individual synapses. For each hemidiaphragm/animal, we quantified 
200–300 NMJs across the entire hemidiaphragm, and we expressed the 
data for each NMJ phenotype as the percentage of total NMJs. We 
performed this analysis on 3–4 animals per group. Each individual an-
imal is represented by a separate circle or triangle in Fig. 3M. We con-
ducted this NMJ morphological analysis to confirm that there was no 
diaphragm denervation that could have resulted from factors such as 
PhMN damage or even PhMN death, as well as to show that LAR peptide 
administration did not impact diaphragm innervation by PhMNs. 
3.7.9. Spinal cord and brainstem dissection 
Rats were euthanized with Euthasol. After the diaphragms were 
excised, animals were perfused transcardially 8 weeks after injury with 
saline, followed by cold 4% paraformaldehyde. After post-fixation in the 
same fixative overnight, tissues were washed with 1xPBS and trans-
ferred to 30% sucrose solution in 1xPBS. 
3.7.10. Immunohistochemistry 
Spinal cord tissue extending from 10 mm rostral to the lesion to 10 
mm caudal to the lesion (20 mm long, containing lesion area) was 
embedded in OCT and cryosectioned parasagittally on a Microm HM550 
cryostat Microtome (Thermo Scientific) (40 μm thick). The free-floating 
sections were blocked/permeabilized with a solution of 5% Normal Goat 
Serum (Vector Laboratories, Burlingame, California), 0.2% Triton X-100 
(Amresco, Solon, Ohio), diluted in PBS (primary and secondary anti-
bodies were diluted in this solution as well) for 1 h at room temperature 
and then processed with primary antibodies at 4 ◦C overnight using 
procedures for immunocytochemistry, as described previously. Multiple 
primary antibodies were used in combination, including rabbit glial 
fibrillary acidic protein (GFAP) (1:500, RRID: AB_10013382, Dako), 
rabbit-anti-dsRed (1:500, Living Colors DsRed pAb, RRID: AB 
_10013483; Takara Bio USA, Mountain View, CA, USA) to enhance 
mCherry fluorescence, goat-anti-CTB (1:10,000; RRID: AB_10013220; 
List Biological Laboratories), mouse-anti-vesicular glutamate trans-
porter 2 (1:250, RRID: AB_2187552; MilliporeSigma), rabbit-anti-5- 
hydroxy-tryptamine (5-HT; 1:15,000, RRID: AB_572263; ImmunoStar, 
Hudson, WI, USA). All secondary antibodies were used at 1:200 dilution 
for 1 h at room temperature and included: Alexa Fluor 647 AffiniPure 
Donkey anti-mouse, Alexa Fluor 488 AffiniPure donkey anti-goat, Alexa 
Fluor 647-conjugated donkey anti-goat, Alexa Fluor 488 AffiniPure 
donkey anti-rabbit (Jackson Immuno-Research Laboratories), and Alexa 
Fluor 594-conjugated donkey anti-rabbit (Abcam, Cambridge, MA, 
USA). The sections were mounted, dehydrated, covered with Fluo-
rSave™ Reagent (Millipore) and then added with cover slips. Stained 
sections were examined using a Leica SP8 confocal microscope (Leica 
Microsystems Inc., Buffalo Grove, IL). Image analysis was performed 
using Image J (NIH), as described previously (Urban et al., 2019a). 
3.7.11. Counts of transduced rVRG neurons 
To quantify numbers of AAV-mCherry transduced rVRG neuron cell 
bodies, 40 μm transverse sections of the medulla were imaged with a 
Zeiss Axio M2 Imager (Carl Zeiss Inc.). Images were then optically 
“stitched” by MetaMorph software (Molecular Devices; RRID: 
SCR_002368) to generate a complete image of the entire medulla sec-
tion. The number of mCherry+ transduced neurons in the rVRG per 
section were counted and averaged over multiple sections to obtain a 
single value for each animal. 
3.7.12. Lesion size measurement 
Lesion edge was defined as the interface between the GFAP-negative 
and GFAP-positive regions surrounding the lesion core. GFAP-negative 
tissue was defined as tissue that had little GFAP immunoreactivity, 
with few GFAP-positive cells or processes. GFAP-positive processes 
formed a defined boundary between GFAP-positive and GFAP-negative 
locations. Lesion borders were outlined manually based on images 
taken with a 20× objective lens. In each quantified sagittal section, 
rostral-caudal distance between the rostral and caudal lesion borders 
was measured at three locations (i.e. at dorsal, medial and rostral por-
tions of the lesion in the sagittal section) using the NIH ImageJ analysis 
software, and three sections were averaged within an individual animal. 
3.7.13. Spinal cord cresyl violet staining 
40 μm transverse spinal cord sections were retrieved from the − 20 ◦C 
freezer and dried at room temperature overnight. Slides were then 
dipped in dH2O for 30 s. Slides were next placed into a cresyl violet 
solution (0.4% cresyl violet, 6% 1 M sodium acetate, 34% 1 M acetic 
acid) for 18 min. Finally, slides were placed in baths of dH2O, 70% 
ethanol, 95% ethanol, 100% ethanol and xylene. Slides were then 
mounted with poly-mount xylene (Polysciences, Warrington, Pennsyl-
vania) and coverslips were added. Slides were then kept at room tem-
perature for analysis. 
3.7.14. Analysis of rVRG axon regeneration and sprouting 
To visualize rVRG axons in animals with either ipsilateral or 
contralateral injections of AAV2-mCherry into the rVRG, sagittal sec-
tions were enhanced with a rabbit Living Colors DsRed Polyclonal 
antibody 1:500 (Takara Bio Company) and an Alexa-594-conjugated 
secondary antibody. For mCherry-labeled axon regeneration quantifi-
cation (i.e. in rats injected with mCherry into ipsilateral rVRG), in the 
sagittal sections of cervical spinal cord containing the lesion site, the 
average number of mCherry-labeled axons that traversed through 
various distances were counted at the lesion site and in intact rostral and 
caudal spinal cord, using rostral lesion-intact border as the distance 
starting point (Urban et al., 2019b). For this rVRG axon regeneration 
quantification, we counted numbers of rVRG axon profiles that crossed a 
straight line (running from the dorsal to ventral part of the section) 
placed at each of the rostral-caudal distances presented in the graph in 
Fig. 5H. The same mCherry+ axon could be counted at multiple dis-
tances (or even at the same distance because of branching and/or u- 
turns). With this quantification, we are counting numbers of axon pro-
files at various rostral-caudal distances to assess density of rVRG axon 
growth. 
For quantification of rVRG axon sprouting within the PhMN pool (i.e. 
in animals injected with AAV2-mCherry into contralateral rVRG), we 
quantified axon profile numbers within a constant-area size box (500 
μm × 500 μm) at the location of CTB-labeled PhMNs on the side of C2 
hemisection. Numbers of mCherry-labeled rVRG axons were obtained 
and averaged separately at C3, C4 and C5 regions of spinal cord: +1.5 
(mm), +3.0 (mm), and + 4.5 (mm), respectively (Urban et al., 2019b). 
4–5 sections were analyzed per rat, and 4–5 rats per group were quan-
tified. Similar to rVRG axon regeneration analysis described above, the 
same rVRG axon could be counted more than once in this area box 
because of branching and/or because the axon exited and re-entered the 
40 μm tissue section in the z-plane and/or x-y plane. 
For both rVRG axon regeneration and rVRG axon sprouting, we 
present results as axon profiles. We identified an axon profile quanti-
tatively as a continuous segment of mCherry-labeled axon that measures 
at least 10 μm in length. 
3.7.15. Analysis of putative rVRG-PhMN monosynaptic connections 
To quantify putative monosynaptic connections between pre- 
synaptic mCherry+/Vesicular Glutamate Transporter 2 (VGLUT2)+
rVRG axon terminals and post-synaptic CTB+ PhMNs, longitudinal sec-
tions were triple immunostained with antibodies directed against Living 
Colors DsRed, VGLUT2 (Sigma) and Cholera Toxin B Subunit (List Bio-
logical Laboratories). For quantification of the number of putative 
monosynaptic connections at C3, C4 and C5 regions ipsilateral to the 
lesion, mCherry/VGLUT2 double-positive signals directly pre-synaptic 
to the somata of CTB+ PhMNs were identified under orthogonal view 
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in single-z confocal images (Urban et al., 2019b). We confirmed overlay 
of the VGLUT2 and mCherry signals in both the x-y and z planes. Using 
the same approach, we also quantified numbers of putative mCherry− / 
VGlut2+ excitatory synapses onto CTB+ PhMNs (from non-rVRG excit-
atory neurons) at C3 on the side of hemisection. 
3.7.16. Analysis of serotonergic axons 
For serotonin axon labeling, parasagittal sections were immuno-
stained with a rabbit anti-5-HT antibody (ImmunoStar) and Alexa-488- 
conjugated secondary antibody. For serotonergic axon quantification, 
the individual fibers stained by 5-HT antibody within a constant-area 
size box (500 μm × 500 μm) at the location of CTB-labeled PhMNs at 
C3, C4 and C5 regions were traced and the total length of all traced 5-HT 
axons was calculated from two random sections in each rat. Specifically, 
this sprouting quantification was performed within the ipsilateral PhMN 
pool on the side of C2 hemisection (Urban et al., 2019a). 
3.7.17. Statistical analysis 
All data are presented as the mean ± SEM. OriginPro 8.0 (OriginLab 
Corp.) was used for all statistical analysis. Data were analyzed with a 
one-way analysis of variance followed by a Tukey’s multiple comparison 
test or a two-tailed Student’s t-test. Pearson Correlation was used to 
examine correlation. P value <0.05 was considered significant. 
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